Skip to main content

Table 1 Baseline characteristics (safety analysis set)

From: Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

 

Placebo (n = 442)

Mirabegron Total (n = 445)

Female sex, n (%)

324 (73.3)

317 (71.2)

Age, mean ± SD

71.9 ± 6.0

71.7 ± 5.5

Age ≥75 years, n (%)

124 (28.1)

125 (28.1)

BMI, kg/m2, mean ± SD

30.2 ± 6.4

29.7 ± 6.3

 Category, n (%)

  <25

91 (20.6)

108 (24.3)

  ≥25–<30

150 (33.9)

157 (35.3)

  ≥30

201 (45.5)

180 (40.4)

Ethnicity, n (%)

 Not Hispanic or Latino

395 (89.4)

401 (90.1)

 Hispanic or Latino

43 (9.7)

41 (9.2)

 Unknown

4 (0.9)

3 (0.7)

Race, n (%)

 White

357 (80.8)

348 (78.2)

 Asian

54 (12.2)

59 (13.3)

 Black or African American

25 (5.7)

33 (7.4)

 Other

6 (1.4)

5 (1.1)

Country, n (%)

 United States

389 (88.0)

385 (86.5)

 Canada

53 (12.0)

60 (13.5)

Charlson Comorbidity Index score, mean ± SD

2.3 (1.2)

2.3 (1.2)

History of psychiatric disorders

 Depression

72 (16.3)

81 (18.2)

 Insomnia

82 (18.6)

57 (12.8)

 Anxiety

42 (9.5)

59 (13.3)

 Sleep disorder

5 (1.1)

6 (1.3)

 Attention deficit/hyperactivity disorder

4 (0.9)

4 (0.9)

 Libido decreased

4 (0.9)

4 (0.9)

 Bipolar disorder

3 (0.7)

4 (0.9)

 Nicotine dependence

5 (1.1)

1 (0.2)

 Adjustment disorder with depressed mood

2 (0.5)

1 (0.2)

 Initial insomnia

0

2 (0.4)

 Persistent depressive disorder

0

2 (0.4)

 Stress

0

2 (0.4)

 Major depression

1 (0.2)

1 (0.2)

 Adjustment disorder

0

1 (0.2)

 Alcoholism

0

1 (0.2)

 Burnout syndrome

0

1 (0.2)

 Depressed mood

0

1 (0.2)

 Drug abuse

0

1 (0.2)

 Drug dependence

0

1 (0.2)

 Emotional disorder

0

1 (0.2)

 Mood swings

0

1 (0.2)

 Nervousness

0

1 (0.2)

 Post-traumatic stress disorder

0

1 (0.2)

 Premature ejaculation

0

1 (0.2)

 Anxiety disorder

1 (0.2)

0

 Claustrophobia

1 (0.2)

0

 Obsessive-compulsive disorder

1 (0.2)

0

MoCA total scorea, n (%)

 Category, n (%)

  Normal (≥26)

305 (69.3)

310 (70.0)

  Mild (18–25)

103 (23.4)

112 (25.3)

  Moderate (10–17)

3 (0.7)

3 (0.7)

  Severe (<10)

0

0

  Missing

29 (6.6)

18 (4.1)

  1. Safety analysis set (SAF): all randomized subjects who received ≥1 dose of study medication
  2. MoCA Montreal Cognitive Assessment, SD standard deviation
  3. aN = 440 for placebo and 443 for mirabegron total